Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2022 Filed Feb 5, 2022 00:14 UTC |
PENDARVIS DAVIDChief Administration Officer
|
SaleResMed Common Stock | 1,544 | $232.87 | $359,551.28 |
DisclosureSEC source: 0001127602-22-003444 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administration Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,491 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 22:40 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock Options · Derivative | 8,000 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-22-001741 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,098 Underlying: ResMed Common Stock · 8,000 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 22:40 UTC |
Douglas Robert AndrewPresident and COO
|
SaleResMed Common Stock | 8,000 | $247.80 | $1,982,400.00 |
DisclosureSEC source: 0001127602-22-001741 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,175 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 22:40 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock | 8,000 | $58.24 | $465,920.00 |
DisclosureSEC source: 0001127602-22-001741 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:37 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-001718 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,315 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:37 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $241.94 | $1,372,990.77 |
DisclosureSEC source: 0001127602-22-001718 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,229 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $239.63 to $246.44. The price reported above reflects the weighted average sale price. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:37 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-001718 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 10, 2022 Filed Jan 11, 2022 22:18 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,500 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-001337 · form4.xml · derivative · entry 3 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: ResMed Common Stock · 2,500 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| January 10, 2022 Filed Jan 11, 2022 22:18 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $235.00 | $587,500.00 |
DisclosureSEC source: 0001127602-22-001337 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,354 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 10, 2022 Filed Jan 11, 2022 22:18 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock | 2,500 | $57.76 | $144,400.00 |
DisclosureSEC source: 0001127602-22-001337 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 23:12 UTC |
PENDARVIS DAVIDChief Administration Officer
|
SaleResMed Common Stock | 1,544 | $258.52 | $399,154.88 |
DisclosureSEC source: 0001127602-22-000662 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administration Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,035 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 22:42 UTC Amendment |
Leong JustinPresident, Asia Latin America
|
Tax withholdingReMed Common Stock | 562 | $259.47 | $145,822.14 |
DisclosureSEC source: 0001127602-22-000624 · form4a.xml · nonDerivative · entry 2 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,295 F2 · kind: Amended to report the disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018, 11/21/2019 and 11/19/2020. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 16:24 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock Options · Derivative | 8,000 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-21-031222 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,098 Underlying: ResMed Common Stock · 8,000 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 16:24 UTC |
Douglas Robert AndrewPresident and COO
|
SaleResMed Common Stock | 8,000 | $256.52 | $2,052,160.00 |
DisclosureSEC source: 0001127602-21-031222 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,175 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 16:24 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock | 8,000 | $58.24 | $465,920.00 |
DisclosureSEC source: 0001127602-21-031222 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 16:23 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-21-031221 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,990 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 16:23 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $255.53 | $1,450,141.26 |
DisclosureSEC source: 0001127602-21-031221 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,229 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $253.51 to 259.63. The price reported above reflects the weighted average sale price. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 16:23 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-21-031221 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 20:48 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,500 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-21-030901 · form4.xml · derivative · entry 3 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: ResMed Common Stock · 2,500 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 20:48 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $264.92 | $662,300.00 |
DisclosureSEC source: 0001127602-21-030901 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,354 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 20:48 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock | 2,500 | $57.76 | $144,400.00 |
DisclosureSEC source: 0001127602-21-030901 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 21:57 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,544 | $257.93 | $398,243.92 |
DisclosureSEC source: 0001127602-21-030371 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,579 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 00:16 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 2,400 | $256.84 | $616,416.00 |
DisclosureSEC source: 0001127602-21-029962 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,721 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 00:32 UTC |
Farrell Michael J.Chief Executive Officer
|
GiftResMed Common Stock | 3,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029967 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lisette & Michael Farrell Family Foundation Disclosed balance after: 3,880 F2 · kind: Gift of shares transferred from The Lisette and Michael Farrell Family Trust, Mr. Farrell retains dispositive power over the gifted shares. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 00:32 UTC |
Farrell Michael J.Chief Executive Officer
|
GiftResMed Common Stock | 3,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029967 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lisette and Michael Farrell Family Trust Disclosed balance after: 5,090 F1 · kind: Gift of shares transferred to The Lisette and Michael Farrell Foundation, Mr. Farrell retains dispositive power over remaining shares. Read SEC document |
| November 24, 2021 Filed Nov 30, 2021 00:56 UTC |
Leong JustinPresident, Asia Latin America
|
Tax withholdingReMed Common Stock | 1,339 | $254.81 | $341,190.59 |
DisclosureSEC source: 0001127602-21-029802 · form4.xml · nonDerivative · entry 1 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,391 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 23, 2021 Filed Nov 30, 2021 02:56 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GiftResMed Common Stock | 791 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029820 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 234,995 F1 · kind: Represents a gift of shares to Fidelity Charitable, a donor advised fund. Mr. Douglas has no beneficial interest, control or dispositive power over the gifted shares. F2 · balance_after: Includes a transfer of shares between direct and indirect holdings on 11/23/2021. Read SEC document |
| November 22, 2021 Filed Nov 23, 2021 23:24 UTC |
Burt CarolDirector
|
SaleResMed Common Stock | 1,500 | $260.00 | $390,000.00 |
DisclosureSEC source: 0000943819-21-000043 · primary_doc.xml · nonDerivative · entry 1 Burt Carol · CIK 0001493926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,095 Read SEC document |
| November 19, 2021 Filed Nov 18, 2021 22:44 UTC |
Farrell Michael J.Chief Executive Officer
|
GiftResMed Common Stock | 44,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029587 · form4.xml · nonDerivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,229 F4 · kind: Gift of shares to the Farrell Legacy Trust. Mr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 01:13 UTC Amendment |
Leong JustinPresident, Asia Latin America
|
GrantReMed Common Stock | 638 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029616 · form4a.xml · nonDerivative · entry 3 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,730 F3 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on November 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 22:44 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 4,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029587 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,479 F3 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on November 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 22:41 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 1,161 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029582 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,354 F2 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on November 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 22:40 UTC |
Leong JustinPresident, Asia Latin America
|
GrantReMed Common Stock | 638 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029581 · form4.xml · nonDerivative · entry 2 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,495 F2 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on November 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 22:38 UTC |
Ghoshal KaushikPresident, SaaS Business
|
GrantResMed Common Stock | 697 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029580 · form4.xml · nonDerivative · entry 3 Ghoshal Kaushik · CIK 0001881922 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,171 F3 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on November 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 22:03 UTC |
Hollingshead JamesPresident, Sleep Business
|
GrantResMed Common Stock | 316 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029558 · form4.xml · nonDerivative · entry 4 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,121 F4 · kind: Represents performance-based restricted stock units granted on July 1, 2020. The shares were earned on November 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 22:03 UTC |
Hollingshead JamesPresident, Sleep Business
|
GrantResMed Common Stock | 1,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029558 · form4.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,805 F3 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on November 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 22:01 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GrantResMed Common Stock | 2,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029557 · form4.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,554 F3 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on November 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 21:04 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029539 · form4.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,123 F3 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on November 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 01:11 UTC |
Leong JustinPresident, Asia and LATAM
|
GrantResMed Common Stock Options · Derivative | 8,134 | $0.00 Strike: $263.16 | $0.00 |
DisclosureSEC source: 0000943819-21-000040 · primary_doc.xml · derivative · entry 2 Leong Justin · CIK 0001825782 · President, Asia and LATAM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,134 Underlying: ResMed Common Stock · 8,134 shares Expires 2028-11-18 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2022, 2023 and 2024. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 01:46 UTC |
Drexler KarenDirector
|
GrantResMed Common Stock Options · Derivative | 1,695 | $0.00 Strike: $263.16 | $0.00 |
DisclosureSEC source: 0000943819-21-000042 · primary_doc.xml · derivative · entry 2 Drexler Karen · CIK 0001504699 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,695 Underlying: ResMed Common Stock · 1,695 shares Expires 2028-11-18 F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest on the earlier of (i) the first November 11 following the Grant Date, or (ii) the date of the first (1st) annual meeting of stockholders of the Company following the Grant Date. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 01:46 UTC |
Drexler KarenDirector
|
GrantResMed Common Stock | 478 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-21-000042 · primary_doc.xml · nonDerivative · entry 1 Drexler Karen · CIK 0001504699 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,459 F1 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2022, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 01:17 UTC Amendment |
Burt CarolDirector
|
GrantResMed Common Stock | 956 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-21-000041 · primary_doc.xml · nonDerivative · entry 1 Burt Carol · CIK 0001493926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,551 F1 · balance_after: Corrects number of securities beneficially owned after reported award. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 01:00 UTC |
PENDARVIS DAVIDChief Administration Officer
|
GrantResMed Common Stock Options · Derivative | 5,931 | $0.00 Strike: $263.16 | $0.00 |
DisclosureSEC source: 0000943819-21-000039 · primary_doc.xml · derivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administration Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,931 Underlying: ResMed Common Stock · 5,931 shares Expires 2028-11-18 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2022, 2023 and 2024. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 00:53 UTC |
Douglas Robert AndrewPresident and COO
|
GrantResMed Common Stock Options · Derivative | 15,252 | $0.00 Strike: $263.16 | $0.00 |
DisclosureSEC source: 0000943819-21-000038 · primary_doc.xml · derivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,252 Underlying: ResMed Common Stock · 15,252 shares Expires 2028-11-18 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2022, 2023 and 2024. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 00:45 UTC |
FARRELL PETER CDirector
|
GrantResMed Common Stock Options · Derivative | 1,695 | $0.00 Strike: $263.16 | $0.00 |
DisclosureSEC source: 0000943819-21-000037 · primary_doc.xml · derivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,695 Underlying: ResMed Common Stock · 1,695 shares Expires 2028-11-18 F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest on the earlier of (i) the first November 11 following the Grant Date, or (ii) the date of the first (1st) annual meeting of stockholders of the Company following the Grant Date. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 00:45 UTC |
FARRELL PETER CDirector
|
GrantResMed Common Stock | 478 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-21-000037 · primary_doc.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,102 F1 · balance_after: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2022, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 00:00 UTC |
RESMED INCDirector
|
GrantResMed Common Stock | 956 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-21-000036 · primary_doc.xml · nonDerivative · entry 1 RESMED INC · CIK 0000943819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,823 F1 · shares: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2022, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 23:57 UTC |
Gill HarjitDirector
|
GrantResMed Common Stock | 956 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-21-000035 · primary_doc.xml · nonDerivative · entry 1 Gill Harjit · CIK 0001759311 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,185 F1 · shares: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2022, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 23:53 UTC |
De Witte JanDirector
|
GrantResMed Common Stock | 956 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-21-000034 · primary_doc.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,989 F1 · shares: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2022, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 23:39 UTC |
TAYLOR RONALD RDirector
|
GrantResMed Common Stock | 956 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-21-000033 · primary_doc.xml · nonDerivative · entry 1 TAYLOR RONALD R · CIK 0001161920 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,725 F1 · shares: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2022, or the annual shareholders meeting in the year following the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.